Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts

Frédéric Lallemand; Mathieu Schmitt; Jean Louis Bourges; Robert Gurny; Simon Benita; Jean Sébastien Garrigue

doi:10.1016/j.ejpb.2017.03.006

Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts

Frédéric Lallemand, Mathieu Schmitt, Jean Louis Bourges, Robert Gurny, Simon Benita, Jean Sébastien Garrigue^*

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Review article › peer-review

140 Scopus citations

Abstract

Local ocular delivery of cyclosporine A (CsA) is the preferred method for CsA delivery as a treatment for ocular inflammatory diseases such as uveitis, corneal healing, vernal keratoconjunctivitis and dry eye disease. However, due to the large molecular weight and hydrophobic nature of CsA and the natural protective mechanisms of the eye, achieving therapeutic levels of CsA in ocular tissues can be difficult. This review gives a comprehensive overview of the current products available to clinicians as well as emerging drug delivery solutions that have been developed at both the academic and industry levels.

Original language	English
Pages (from-to)	14-28
Number of pages	15
Journal	European Journal of Pharmaceutics and Biopharmaceutics
Volume	117
DOIs	https://doi.org/10.1016/j.ejpb.2017.03.006
State	Published - 1 Aug 2017

Bibliographical note

Publisher Copyright:
© 2017 The Authors

Keywords

Cyclosporine
Emulsion
Hydrogel
Ocular delivery
Pipeline products
Solution

Access to Document

10.1016/j.ejpb.2017.03.006

Cite this

@article{f96663736d0244298f99eab76d4f87f1,

title = "Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts",

abstract = "Local ocular delivery of cyclosporine A (CsA) is the preferred method for CsA delivery as a treatment for ocular inflammatory diseases such as uveitis, corneal healing, vernal keratoconjunctivitis and dry eye disease. However, due to the large molecular weight and hydrophobic nature of CsA and the natural protective mechanisms of the eye, achieving therapeutic levels of CsA in ocular tissues can be difficult. This review gives a comprehensive overview of the current products available to clinicians as well as emerging drug delivery solutions that have been developed at both the academic and industry levels.",

keywords = "Cyclosporine, Emulsion, Hydrogel, Ocular delivery, Pipeline products, Solution",

author = "Fr{\'e}d{\'e}ric Lallemand and Mathieu Schmitt and Bourges, {Jean Louis} and Robert Gurny and Simon Benita and Garrigue, {Jean S{\'e}bastien}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors",

year = "2017",

month = aug,

day = "1",

doi = "10.1016/j.ejpb.2017.03.006",

language = "אנגלית",

volume = "117",

pages = "14--28",

journal = "European Journal of Pharmaceutics and Biopharmaceutics",

issn = "0939-6411",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Cyclosporine A delivery to the eye

T2 - A comprehensive review of academic and industrial efforts

AU - Lallemand, Frédéric

AU - Schmitt, Mathieu

AU - Bourges, Jean Louis

AU - Gurny, Robert

AU - Benita, Simon

AU - Garrigue, Jean Sébastien

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Local ocular delivery of cyclosporine A (CsA) is the preferred method for CsA delivery as a treatment for ocular inflammatory diseases such as uveitis, corneal healing, vernal keratoconjunctivitis and dry eye disease. However, due to the large molecular weight and hydrophobic nature of CsA and the natural protective mechanisms of the eye, achieving therapeutic levels of CsA in ocular tissues can be difficult. This review gives a comprehensive overview of the current products available to clinicians as well as emerging drug delivery solutions that have been developed at both the academic and industry levels.

AB - Local ocular delivery of cyclosporine A (CsA) is the preferred method for CsA delivery as a treatment for ocular inflammatory diseases such as uveitis, corneal healing, vernal keratoconjunctivitis and dry eye disease. However, due to the large molecular weight and hydrophobic nature of CsA and the natural protective mechanisms of the eye, achieving therapeutic levels of CsA in ocular tissues can be difficult. This review gives a comprehensive overview of the current products available to clinicians as well as emerging drug delivery solutions that have been developed at both the academic and industry levels.

KW - Cyclosporine

KW - Emulsion

KW - Hydrogel

KW - Ocular delivery

KW - Pipeline products

KW - Solution

UR - http://www.scopus.com/inward/record.url?scp=85016520737&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2017.03.006

DO - 10.1016/j.ejpb.2017.03.006

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 28315447

AN - SCOPUS:85016520737

SN - 0939-6411

VL - 117

SP - 14

EP - 28

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

ER -

Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this